Named Bioactive Compounds · Compound
Xanthohumol (Chalcone)
Moderate Evidenceflavonoid
Hermetica Superfood Encyclopedia
Xanthohumol is a prenylated chalcone flavonoid found primarily in hops that exhibits potent anti-cancer and neuroprotective properties. It works by activating the Nrf2 antioxidant pathway and directly inhibiting cancer cell proliferation with IC50 values of 2.6-4.1 μM in colon cancer cells.
Xanthohumol is a prenylated chalcone naturally found in the female hop cones (Humulus lupulus), comprising 0.1-1% of dry weight. It is biosynthesized through a polyketide synthase pathway beginning with L-phenylalanine, and appears as solid yellow crystals that contribute to the bitterness and flavor of hops and beer.
The available research consists primarily of in vitro and preclinical studies demonstrating anti-cancer and neuroprotective effects. No human clinical trials, randomized controlled trials, or meta-analyses with PubMed PMIDs were identified in the current literature review.
No clinically studied dosage ranges for human use are available in the current research. The existing data are limited to in vitro concentrations (micromolar ranges) which cannot be translated to human dosing recommendations. Consult a healthcare provider before starting any new supplement.
Xanthohumol is a prenylated chalcone (C₂₁H₂₂O₅, MW 354.4 g/mol) and is not a nutritional macronutrient source. It is a specialized bioactive polyphenolic compound found primarily in the female inflorescences (strobiles) of hops (Humulus lupulus L.). Key profile details: • Primary source concentration: Hops contain approximately 0.1–1.0% xanthohumol by dry weight, making it the most abundant prenylated flavonoid in hops. • Beer content: Conventional beers contain only ~0.002–0.628 mg/L due to thermal isomerization during brewing (most xanthohumol converts to isoxanthohumol during wort boiling, with conversion rates of ~80–90%). Xanthohumol-enriched beers have been developed containing up to ~10 mg/L. • Dietary supplement forms: Typically available in hop extract capsules providing 5–50 mg per dose, often standardized to ≥1–5% xanthohumol content. • Bioactive compound class: Prenylated chalcone (open-ring flavonoid precursor); characterized by a 2',4',6',4-tetrahydroxy-3'-prenylchalcone structure with a prenyl (3-methylbut-2-enyl) side chain critical for biological activity. • Lipophilicity: LogP ~4.26, indicating high lipophilicity; poorly water-soluble (~1.3 mg/L in water at 25°C). • Bioavailability: Oral bioavailability is low, estimated at approximately 11–33% in rodent models. Absorbed primarily in the small intestine; undergoes extensive first-pass hepatic metabolism via phase I (CYP450-mediated oxidation and demethylation) and phase II conjugation (glucuronidation and sulfation). Gut microbiota convert xanthohumol to 8-prenylnaringenin (a potent phytoestrogen) and other metabolites. Plasma Cmax following oral dosing in humans (~20 mg) is approximately 0.02–0.15 μM, with Tmax of ~1–4 hours and elimination half-life of ~18–20 hours. • Key functional groups contributing to bioactivity: α,β-unsaturated carbonyl (Michael acceptor enabling Nrf2/Keap1 electrophilic modification), prenyl group (enhancing membrane interaction and potency over non-prenylated analogs by 5–10 fold), and multiple hydroxyl groups (antioxidant radical scavenging, ORAC value significantly higher than many conventional flavonoids). • No significant vitamin or mineral content as an isolated compound. • Encapsulation strategies (cyclodextrin inclusion complexes, liposomal formulations, solid lipid nanoparticles) have been shown to improve aqueous solubility by 5–40 fold and oral bioavailability by 2–10 fold in preclinical models.
Xanthohumol activates the Nrf2 transcription factor, which upregulates antioxidant enzymes like glutathione S-transferase and NAD(P)H quinone oxidoreductase to protect against oxidative stress. It also inhibits cancer cell growth by interfering with cell cycle progression and inducing apoptosis through multiple pathways including NF-κB suppression.
Current evidence for xanthohumol comes primarily from in vitro preclinical studies using human cancer cell lines. Studies show cytotoxic activity against colon cancer cells with IC50 values of 2.6-4.1 μM, along with similar effects in breast and prostate cancer models. Human clinical trials are limited, with most research focusing on cellular and animal models to establish safety profiles and bioavailability. The evidence base remains in early stages with no large-scale human efficacy studies completed.
Xanthohumol appears well-tolerated in preclinical studies with no major acute toxicity reported at tested concentrations. However, comprehensive human safety data is limited due to lack of extensive clinical trials. Potential interactions with cytochrome P450 enzymes may affect metabolism of certain medications, though specific drug interactions have not been thoroughly studied. Safety during pregnancy and breastfeeding has not been established, so use should be avoided in these populations.
